文献速递肿瘤 PET/CT核素与放射性配体治疗

Al18F-PSMA-BCH用于前列腺癌PET显像的临床前评价与初步临床研究

Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging.
PubMed 文献 · J Nucl Med · 2019-02-22

本研究制备了Al18F标记的PSMA靶向示踪剂Al18F-PSMA-BCH,在22Rv1和PC-3荷瘤小鼠中行小动物PET及生物分布研究,并与68Ga-PSMA-617比较,同时对11例新诊断前列腺癌患者行注射后1h和2h PET/CT显像及辐射剂量估算。结果显示该示踪剂30min内可制备完成,对PSMA解离常数为2.90±0.83 nM,可清晰区分PSMA阳性与阴性肿瘤,11例患者共检出37个肿瘤病灶,27个病灶SUVmax在1至2h间升高(10.60 vs. 14.11),肾脏剂量最高为0.135 mGy/MBq,有效剂量为0.016 mGy/MBq。结论认为Al18F-PSMA-BCH制备便捷、显像能力良好且辐射暴露合理,可作为新型18F PET示踪剂用于前列腺癌显像。

要点

  • Al18F-PSMA-BCH可在30 min内制备完成,对PSMA解离常数为2.90±0.83 nM。
  • 小动物PET可清晰区分22Rv1与PC-3肿瘤,1h摄取分别为7.87%±2.37%和0.54%±0.22% ID/g。
  • 11例患者检出37个病灶,27个病灶SUVmax在1至2h间由10.60升至14.11。

核心结论

  • Al18F-PSMA-BCH制备便捷、产率合理,对前列腺癌具有良好显像能力且辐射暴露合理,可作为新型18F PET示踪剂用于前列腺癌显像。

研究设计与样本

  • 临床前研究在22Rv1(PSMA阳性)和PC-3(PSMA阴性)荷瘤小鼠中行小动物PET及生物分布研究,并与68Ga-PSMA-617在LNCaP荷瘤小鼠中比较。
  • 临床行11例新诊断前列腺癌患者注射后1h和2h PET/CT显像,评估生物分布与初步疗效,并用OLINDA/EXM 2.0软件估算辐射剂量。

主要发现

  • Al18F-PSMA-BCH在30 min内制备完成,对PSMA解离常数为2.90±0.83 nM。
  • 小动物PET可清晰区分22Rv1与PC-3肿瘤,离体生物分布1h摄取分别为7.87%±2.37%和0.54%±0.22% ID/g。
  • 22Rv1肿瘤摄取可被过量PSMA抑制剂ZJ-43明显阻断,PSMA表达器官呈高摄取且后期时间点摄取增加。
  • 11例患者共检出37个肿瘤病灶,27个病灶SUVmax在注射后1至2h间升高(10.60 vs. 14.11)。
  • 高危前列腺癌患者原发灶SUVmax高于中危患者,肾脏估计剂量最高为0.135 mGy/MBq,有效剂量为0.016 mGy/MBq。

关键数值与推荐

  • Al18F-PSMA-BCH对PSMA解离常数为2.90±0.83 nM。
  • 22Rv1与PC-3肿瘤1h摄取分别为7.87%±2.37%和0.54%±0.22% ID/g。
  • 27个病灶SUVmax在1至2h间由10.60升至14.11。
  • 肾脏估计剂量0.135 mGy/MBq,有效剂量0.016 mGy/MBq。

临床怎么用

  • Al18F-PSMA-BCH可在30 min内制备,适合作为18F标记的PSMA靶向前列腺癌PET示踪剂。
  • 注射后1至2h病灶SUVmax升高,提示2h显像可能有助于提高病灶检出。
  • 肾脏为最高估计剂量器官(0.135 mGy/MBq),有效剂量为0.016 mGy/MBq。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-targeted radioligands have played an important role in the diagnosis of prostate cancer. In this study, we developed an Al18F-labeled radiotracer and evaluated its potential for prostate cancer imaging. Methods: Al18F-PSMA-BCH (BCH is Beijing Cancer Hospital) was efficiently prepared manually. The binding affinity to PSMA was evaluated in vitro using the 22Rv1 (PSMA-positive) cell line. Small-animal PET imaging, biodistribution studies of Al18F-PSMA-BCH in mice bearing 22Rv1 and PC-3 (PSMA-negative) xenografted tumors, and a comparison with 68Ga-PSMA-617 in mice bearing LNCaP tumors were performed. PET/CT imaging was performed on 11 newly diagnosed prostate cancer patients at 1 and 2 h after injection. Biodistribution and preliminary efficacy were evaluated, and radiation dosimetry was estimated using OLINDA/EXM 2.0 software. Results: Al18F-PSMA-BCH was prepared within 30 min and was found to bind to PSMA with a dissociation constant of 2.90 ± 0.83 nM. Small-animal PET imaging of Al18F-PSMA-BCH could clearly differentiate 22Rv1 tumors from PC-3 tumors, as confirmed by ex vivo biodistribution data (7.87% ± 2.37% and 0.54% ± 0.22% injected dose/g at 1 h in 22Rv1 and PC-3 tumors, respectively). The uptake of Al18F-PSMA-BCH in 22Rv1 tumors could be substantially blocked by excess ZJ-43, a PSMA inhibitor. High-level accumulation of Al18F-PSMA-BCH was observed in PSMA-expressing organs, with increased uptake at later time points. Thirty-seven tumor lesions were detected in 11 patients, and the SUVmax in 27 lesions increased between 1 and 2 h after injection (10.60 vs. 14.11). The SUVmax in primary lesions in patients with high-risk prostate cancer was higher than that in patients with intermediate-risk prostate cancer. The kidneys received the highest estimated dose, 0.135 mGy/MBq, and the effective dose was 0.016 mGy/MBq. Conclusion: Al18F-PSMA-BCH was conveniently prepared with a reasonable yield within 30 min and showed a promising imaging capability for prostate cancer with reasonable radiation exposure. Al18F-PSMA-BCH can be used for prostate cancer imaging as a novel 18F PET radiotracer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu T, Liu C, Xu X, et al. Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging. J Nucl Med. 2019. PMID: 30796170. doi:10.2967/jnumed.118.221671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。